Collaboration & Partners
The clinical development strategies aim to achieve product approvals in multiple disease areas.
Collaboration Opportunities
In addition to Cell to Cure’s in-house clinical development programs, we also pursue a strategic partnering and sublicensing approach to expand the reach and application of our technology.
We actively seek commercial and academic partners to help explore, advance and apply our technology in disease areas where our cell products may offer therapeutic benefit.
We see potential collaboration opportunities in therapeutic areas where stem cells have already shown clinical potential, or in new indications where access to a scalable, GMP-grade, off-the-shelf cell product will enable the development of novel treatment approaches.
Are You Our Next Partner?
We are looking for partners who can contribute to realising the full potential of our platform whether through preclinical research, clinical trials, or by integrating our cell products into existing development programs.
Cell to Cure is open to out licensing our proprietary technology to qualified partners for specific therapeutic areas.
If you are interested in exploring collaboration, partner or licensing opportunities, we invite you to get in touch with us.
If you are interested in exploring collaboration, partner or licensing opportunities, we invite you to get in touch with us.
Collaboration with Endeavour Cells
Cell to Cure ApS has entered a sublicensing agreement with Endeavour Cells ApS, granting the rights to develop, manufacture, and commercialise our cell-based therapies for autism spectrum disorder, attention deficit hyperactivity disorder, attention deficit disorder , and other eterogeneous neurodevelopmental disorders—with or without associated gastrointestinal symptoms.
A collaboration agreement has also been entered between Endeavour Cells that includes clinical product management, services and strategic oversight from Cell to Cure ApS.